BioXcel Therapeutics
BTAI
116 hedge funds and large institutions have $475M invested in BioXcel Therapeutics in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 51 increasing their positions, 32 reducing their positions, and 19 closing their positions.
59% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 32
8% more call options, than puts
Call options by funds: $11.3M | Put options by funds: $10.5M
0.35% less ownership
Funds ownership: 3.15% → 2.8% (-0.35%)
1% less funds holding
Funds holding: 117 → 116 (-1)
5% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 19
16% less capital invested
Capital invested by funds: $567M → $475M (-$92M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$13.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.5M |
| 3 |
BlackRock
New York
|
+$7.76M |
| 4 |
Two Sigma Investments
New York
|
+$7.51M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$6.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$37.4M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$34.1M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$25.3M |
| 4 |
State Street
Boston,
Massachusetts
|
-$20M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OCM
126
Ovata Capital Management
Hong Kong
| – | -$231K | -313 | Closed |
|
|
TC
127
TwinBeech Capital
Purchase,
New York
| – | -$208K | -282 | Closed |
|
|
SO
128
STRS Ohio
Columbus,
Ohio
| – | -$184K | -250 | Closed |
|
|
OSAM
129
O'Shaughnessy Asset Management
Stamford,
Connecticut
| – | -$40K | -54 | Closed |
|
130
Barclays
London,
United Kingdom
| – | -$22K | -30 | Closed |
|
|
ASN
131
Advisory Services Network
Atlanta,
Georgia
| – | -$15K | -20 | Closed |
|
|
QT
132
Quantbot Technologies
New York
| – | -$13K | -19 | Closed |
|
|
AF
133
Allworth Financial
Folsom,
California
| – | -$10K | -13 | Closed |
|
|
RPWA
134
Regent Peak Wealth Advisors
Atlanta,
Georgia
| – | -$5K | -6 | Closed |
|
BTAI Hedge Fund Activity: Q1 2021 in Review
116 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q1 2021, worth a combined $475M — down 16% from $567M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of BTAI and 18 opened new positions — a net loss of 1 holder — while 32 trimmed existing stakes and 51 added.
The largest buyer was First Light Asset Management, adding an estimated $13.3M. The largest seller was Citadel Advisors, cutting an estimated $37.4M.
- 116 institutional investors held BioXcel Therapeutics (BTAI) as of Q1 2021, down from 117 in Q4 2020.
- Funds reported $475M of BioXcel Therapeutics stock for Q1 2021, down 16% quarter-over-quarter.
- 18 funds opened new BioXcel Therapeutics positions in Q1 2021 and 19 closed out, a net change of -1 holder.
- The largest BioXcel Therapeutics buyer in Q1 2021 was First Light Asset Management, an estimated $13.3M added.
- The largest BioXcel Therapeutics seller in Q1 2021 was Citadel Advisors, an estimated $37.4M sold.
Based on aggregated 13F filings for Q1 2021.